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Abstract 20 
 21 
Older patients (aged 65 years and over) are the major consumers of medicines and many 22 
barriers affect their ability in taking medicines orally, especially swallowing difficulties. 23 
Moreover, the characteristics of differing medicine formulations might have an impact on 24 
their acceptability in older patients. The aims of this study were to validate a Medicines 25 
Acceptability Questionnaire (MAQ) and to assess acceptability of oral solid medicines in older 26 
ambulatory patients with and without dysphagia. One hundred and fifty six older patients 27 
attending community pharmacies were recruited and attended face to face interviews. Two 28 
questionnaires were administered during the interviews, the validated Sydney Swallow 29 
Questionnaire (SSQ) assessing oral and pharyngeal swallowing function and the newly 30 
developed Medicines Acceptability Questionnaire (MAQ) evaluating patient acceptability of 31 
oral solid medicines. Seventeen (11%) participants displayed symptoms compatible with 32 
swallowing difficulties identified by the SSQ. Participants with swallowing difficulties were 33 
considered themselves more likely to have problems in swallowing tablets and capsules of 34 
large sizes (11 mm and 13 mm tablets and size #00 capsules) compared to participants 35 
without dysphagia. Dispersible/effervescent tablets and orally disintegrating tablets were 36 
considered to be the most acceptable in this cohort, followed by mini-tablets. Chewable 37 
tablets and granules were the least favoured. Consistently higher acceptability scores were 38 
seen in the dysphagic population than in the non-dysphagic population for all of the dosage 39 
forms that were easier to swallow than tablets and capsules. The development of these 40 
formulations will assist in medication taking in older patients with dysphagia and potentially 41 
their adherence to drug treatments.  42 
Keywords: geriatric, elderly, swallow, medication, acceptance, preference 43 
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1. Introduction 47 
Patient acceptability to a pharmaceutical dosage form is critical to ensure adherence and 48 
therapeutic outcomes, especially in children and older people (F. Liu et al., 2014). 49 
Acceptability has previously been defined as “an overall ability of the patient and caregiver 50 
(defined as ‘user’) to use a medicinal product as intended (or authorised)” (P. Kozarewicz, 51 
2014). The European Medicines Agency has required the assessment of patient acceptability 52 
to be an integrated part of paediatric medicinal product development (E. M. A. (EMA), 2013; 53 
P. Kozarewicz, 2014). However, acceptability of medicines in older adults has been largely 54 
overlooked. Older patients (aged 65 years and over) account for 50% of the medicine 55 
prescriptions in the UK (Z. Rajaei-Dehkordi and G. McPherson, 1997). The oral route remains 56 
the most preferred mode for medicine administration; however, there are barriers for older 57 
patients to take medications orally (F. Liu et al., 2014).  Swallowing difficulties (dysphagia) are 58 
common in older people which affect their ability to take oral medicines, especially tablets 59 
and capsules (C. M. Steele et al., 1997; I. Strachan and M. Greener, 2005). Consequently, 60 
medicines are often modified such as crushing tablets or capsules opened to assist 61 
administration to older patients (J. Kelly and D. Wright, 2009; D. Wright, 2002). This leads to 62 
unlicensed used of medicines and can potentially cause ineffective use or toxicity of the 63 
medicine (S. Stegemann et al., 2012).  64 
 65 
Characteristics of a pharmaceutical dosage form, such as the size, shape, and surface texture 66 
of a tablet, have an impact on how easily a solid oral medicine can be swallowed and pass 67 
through the pharynx and oesophagus (K. S. Channer and J. P. Virjee, 1985; K. T. Evans and G. 68 
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M. Roberts, 1981; H. Hey et al., 1982; A. B. Overgaard et al., 2001). Previous knowledge on 69 
these effects has been demonstrated in healthy young subjects; however, this remains 70 
unclear in older people especially those with existing swallowing difficulties. The type of 71 
formulation might be another factor affecting the ability and willingness of older patients to 72 
take their medicines. A number of solid oral dosage forms that are “easier to swallow” than 73 
tablets and capsules have been made available in recent years including orally disintegrating 74 
tablets (ODTs), dispersible tablets, mini-tablets and multi-particulates (granules). As most of 75 
these formulations are designed and developed for paediatric use, acceptability of some of 76 
these dosage forms in children has been reported (I. T. Cohen et al., 2005; J. Motte et al., 77 
2005; D. Nasrin et al., 2005). For older patients who cannot swallow tablets, the availability 78 
of these formulations could be beneficial. The use of dispersible/effervescent tablets and 79 
ODTs has been demonstrated in older patients (A. J. Bayer et al., 1988; J. C. Nelson et al., 80 
2006). Especially, ODTs have been proven to be easier to swallow than conventional tablets 81 
for patients with dysphagia (G. Carnaby-Mann and M. Crary, 2005). However, evidence in the 82 
acceptability of these solid dosage forms in older patients is still sparse. This research is a pilot 83 
study where a Medicines Acceptability Questionnaire (MAQ) was initially developed and 84 
validated before assessing the acceptability of a range of solid oral medicine dosage forms in 85 
older ambulatory patients attending community pharmacies and investigating the association 86 
between patient acceptability and the presence of swallowing difficulties.  87 
 88 
2. Materials and Methods 89 
 90 
2.1 Study population and setting 91 
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The study was approved by the Ethics Committee of University of Hertfordshire 92 
(LMS/SF/UH/00081) and was conducted at community pharmacies in the South East England 93 
area in the UK during October to November 2014. A convenient sample of pharmacies was 94 
recruited to participate in the study.  The pharmacist in charge in each pharmacy was 95 
informed the purpose of the study and approached consecutive patients attending the 96 
pharmacy during week-day (Monday to Friday) opening hours who were eligible for the study. 97 
The eligibility criteria include patients aged 65 years or over and prescribed at least one oral 98 
medicine. No financial incentive was received by the pharmacies for participating in the study. 99 
 100 
Given the stated aims, the primary endpoint of the study was the proportion of primary care 101 
older patients having swallowing difficulties. Based on the literature, prevalence of 102 
swallowing difficulties in community dwelling older adults was estimated as 11% (G. Holland 103 
et al., 2011). Approximately 150 participants would need to be enrolled to ensure a desired 104 
precision of at least 5%. 105 
 106 
2.2 Administration of the Sydney Swallow Questionnaire (SSQ) 107 
The SSQ is a validated questinnarie and composed of 17 questions assessing oral and 108 
pharyngeal swallowing function with responses entered onto a 101 mm visual analog scale 109 
except for question 12 (R. C. Dwivedi et al., 2010; K. L. Wallace et al., 2000). The SSQ was 110 
administered to the participants during an interview which took place in the private 111 
consultation room in the pharmacy. The participant placed a mark on the horizontal line of 112 
the visual analog scale. The first millimeter of the line was disregarded and a score of 0-100 113 
was calculated by measuring the distance from the center of the mark to the first millimeter 114 
of the line for each question. A mark placed within the first millimeter of the line was scored 115 
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as zero. Question 12 contains 6 catagorical responses each representing a score of 0, 20, 40, 116 
60, 80 or 100. The maximum possible total score for the SSQ was 1700, with higher score 117 
indicating greater severity of swallowing dysfunction.  Analogous to the description of Holland 118 
et al. (G. Holland et al., 2011), a score greater than 200 was considered indicating 119 
symptomatic dysphagia.    120 
 121 
2.3 Pilot of the Medicines Acceptability Questionnaire (MAQ) 122 
The MAQ comprised 15 questions evaluating patient acceptability of oral solid medicines. The 123 
questions were developed around three major topics. The first topic (3 items) covers general 124 
health status of the participant, number of oral medicines currently taking and any difficulties 125 
in taking solid oral medicines. The health status of the participant was measured using a 5-126 
point Likert scale. Excellence in general health was ranked as a score of 1 and a score of 5 127 
represented the health perception being poor. The second topic (5 items) evaluates 128 
participants’ perception on the size and shape of tablets and capsules in relation to difficulties 129 
in swallowing. The participants were shown a printed diagram of tablets of varying sizes and 130 
shapes (Appendix). Samples of 9 mm tablets (the middle size of all sizes presented) of each 131 
shape were taped onto the diagram to provide visual representatives of the size and shape. 132 
Participants were also shown samples of hard gelatin capsules (HGC) of different sizes (4#, 3#, 133 
2#, 1#, 0# and 00#). They were then asked from what size they will start to have difficulty to 134 
swallow the tablets and capsules.  135 
 136 
The third topic (7 items) assesses participants’ acceptability of other alternative solid 137 
medicine dosage forms to tablets and capsules, including mini-tablets, granules in a sachet, 138 
dispersible/effervescent tablets, orally disintegrating tablets (ODTs) and chewable tablets. 139 
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These dosage forms are referred to as “alternative solid oral dosage forms” throughout this 140 
article. The participants were shown samples of all formulation types and were given an 141 
explanation of how the formulation should be administered. Mini-tablets were shown to 142 
participants as mini-tablets filled in HGCs. Granules were presented as sprinkles onto food. 143 
Dispersible tablets were presented as a drink with a minimum amount of 60 ml (or half a glass) 144 
water required to dissolve the tablet. ODTs were described as melting/dissolving on the 145 
tongue and chewable tablets were explained as needing to be chewed before swallowing. 146 
They then provided their opinion on the formulation including past experience in using the 147 
formulation, giving a score of 0-10 indicating their acceptance with 10 being the most 148 
acceptable. Open-ended questions were also used to obtain opinions of the participants on 149 
good and bad points of each formulation. The open-ended questions were analysed by 150 
reporting the percentages of participants stating the same comments on a formulation.   151 
 152 
The content/face validity of the MAQ was assessed by two experts in the field acting as 153 
respondents. Cronbach’s alpha test was conducted to evaluate the level of reliability and 154 
internal consistency using the Statistical Package of the Social Sciences (SPSS) version 22.0 155 
(IBM Corp., Armonk, NY, USA). Cronbach’s alpha scores of 0.7 or above were deemed as 156 
acceptable according to Nunnally and Bernstein (J. Nunnally and L. Bernstein, 1994). The MAQ 157 
was administered to the participants during the interview together with the SSQ. The 158 
interviews were conducted by two of the authors (AG and JB). Three pilot interviews were 159 
conducted in the presence of both interviewers to reach a consensus on how to conduct the 160 
interview and the subsequent interviews were conducted by one interviewer per participant.  161 
 162 
2.4 Data analysis  163 
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Data analysis was performed using the Statistical Package of the Social Sciences (SPSS) version 164 
22.0 (IBM Corp., Armonk, NY, USA). The results are reported as mean ± standard deviation 165 
(SD). Spearman’s nonparametric correlation was used to identify the presence of significant 166 
correlations between total SSQ score and age of participants or number of solid oral 167 
medicines taken daily. The Mann-Whitney U test was conducted to assess links between 168 
gender of participants and total SSQ score, and comparing the means of participants’ self-169 
perceived health status between the dysphagia and non-dysphagia group. Chi-Square test 170 
was conducted to evaluate the relationship between dysphagic status of the participant and 171 
difficulty in swallowing tablets and capsules. The Kruskal Wallis test was used to assess 172 
significant relationship between total SSQ score and participants’ self-perceived health status.  173 
 174 
2.5 Materials used to conduct the interviews 175 
Samples of tablets, capsules and other solid dosage forms that were presented to the 176 
participants during interviews are listed in Tables 1 and 2. Samples of formulations were 177 
purchased as commercial products where possible to represent medicines used in real life. 178 
When a suitable commercial product was not identified to represent a formulation, placebo 179 
samples were used (9 mm arched round tablets).  180 
 181 
 182 
3. Results 183 
3.1 Validation of the Medicines Acceptability Questionnaire (MAQ) 184 
The content/face validity of MAQ was established by experts.  Any items where questions 185 
were raised were modified and the revised versions were tested again until there were no 186 
further questions. The total Cronbach’s alpha score was calculated as 0.940 and scores after 187 
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eliminating any items from the questionnaire were in the range of 0.928 – 0.945, indicating 188 
good reliability and internal consistency of the questions. 189 
 190 
3.2 Participant demographics and the Sydney Swallow Questionnaire (SSQ) scores 191 
Fifteen pharmacies were approached and of these 10 (including both chain-pharmacies and 192 
independent pharmacies) agreed to participate in the study. The main reason given by the 193 
pharmacies for refusing to participate was that the pharmacist had limited time available to 194 
help recruiting participants. A total of 165 patients were approached by the pharmacists and 195 
156 (94.5%) were recruited to participate in the study.  The average age of the participants is 196 
74.0 ± 5.7 (mean ± SD) years and 80 (51.3%) participants were females. All participants 197 
completed both the SSQ and the MAQ successfully.  198 
 199 
Seventeen (11%) participants had SSQ scores ≥ 200, indicating symptomatic dysphagia or 200 
swallowing difficulty. The mean total SSQ score across all participants was 92.2 ± 168.7 (mean 201 
± SD, range 0.0-1026.0) and for participants with significant symptoms of dysphagia it was 202 
497.2 ± 246.6 (mean ± SD, range 211.4-1026.0). There was no significant correlation between 203 
age and SSQ dysphagia score (r=0.050, p=0.537) and no statistically significant relationship 204 
between gender and SSQ dysphagia score (r=-0.040, p=0.624).  205 
 206 
The mean score for the self-perceived health status of all participants was 3.2 ± 1.1 (mean ± 207 
SD, 1=excellent and 5=poor). There was a significant correlation between general health 208 
status score and SSQ dysphagia score (r=0.250, p=0.002). The mean health status scores were 209 
3.9 ±1.0 (mean ± SD) and 3.1 ±1.1 (mean ± SD) for participants with and without dysphagia 210 
respectively. On average, the participants were prescribed 5.1 ± 3.8 (mean ± SD) oral solid 211 
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medicines on a daily basis. Sixty five (42%) participants took 5 or more solid oral medicines 212 
daily. A significant relationship was present between number of oral solid formulations taken 213 
daily by the participants and SSQ dysphagia score (r=0.171, p=0.033).  214 
 215 
3.3 Ability to swallow tablets and capsules in patients with and without dysphagia by the MAQ 216 
A total of 12 (7.8%) participants experienced ongoing difficulties in swallowing tablets and 217 
capsules according to the results from the MAQ.  Figure 1 shows percentage of participants 218 
who has chosen the size and shape of tablets that were perceived as starting to cause 219 
difficulty in swallowing. Between 46% and 64% of the participants without swallowing 220 
difficulties (SSQ score lower than 200) reported no problem of swallowing any of the tablets 221 
sizes for the different shapes presented compared to 6%-12% of the participants with 222 
swallowing difficulties (SSQ score higher than 200; Figure 1). The majority of participants with 223 
dysphagia found that tablets of sizes 11 mm and 13 mm might started to cause difficulties in 224 
swallowing; the percentages of participants selecting 11 mm or 13 mm were 52.9%, 52.9%, 225 
58.8% and 64.7% for flat round, arched round, oblong and oval tablets respectively.  226 
 227 
Similar results were observed regarding difficulties in swallowing capsules of different sizes in 228 
participants with and without dysphagia (Figure 2). Around 40% participants with no 229 
dysphagia deemed themselves having no problem of swallowing any of the capsule sizes 230 
presented, compared to only 6% in participants with dysphagia. In participants with 231 
dysphagia, over a third (35%) selected size #00 as that which started to cause problems in 232 
swallowing; however, around 30% of these participants also considered size #2 to be difficult 233 
to swallow.  234 
 235 
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3.4 Acceptability of alternative solid oral dosage forms  236 
A low proportion of participants had had experience of using the alternative solid oral dosage 237 
forms, except for dispersible/effervescent tablets which were referenced mainly to soluble 238 
paracetamol and dispersible aspirin tablets as examples (Table 3). The acceptability scores of 239 
different oral solid dosage forms are shown in Figure 3. Participants described the good/bad 240 
points they considered for each formulation as listed in Table 4.  241 
  242 
12 
 
12 
 
4. Discussion 
A range of medicine formulations have been made available for patients who find it difficult 
to swallow tablets and capsules. However, the acceptability of these formulations in targeted 
patient groups is often unclear. This pilot study is the first attempt to evaluate the 
acceptability of a range of solid oral dosage forms in older patients with and without 
dysphagia, using the newly developed Medicines Acceptability Questionnaire (MAQ). The 
content validity and reliability of the MAQ was established and the results of this study can 
be compared to future investigations. In our study, the prevalence of (symptoms compatible 
with) dysphagia in this older population attending community pharmacies was found to be 
11%. This is in agreement with a study by Holland et al. in which 11.4% of participants of a 
community dwelling older population in England was found to have scores on the SSQ 
compatible with dysphagia (G. Holland et al., 2011).  This also broadly agrees with or is slightly 
lower than other published data on prevalence of dysphagia in older primary care patients (B. 
R. Bloem et al., 1990; P. H. Chen et al., 2009; K. Kawashima et al., 2004). In this study, age and 
gender of the participant did not significantly affect dysphagia score. Studies have reported 
that increasing age is associated with increased severity and prevalence of dysphagia in 
elderly populations (G. Holland et al., 2011; K. Kawashima et al., 2004). However, Szcaesniak 
et al. studied SSQ score in a non-dysphagic population and found that there was no significant 
correlation between age and SSQ score (M. M. Szczesniak et al., 2014). The majority of the 
participants in the current study were non-dysphagic, which might have contributed to the 
non-significant relationship between age and dysphagia score. It is also possible that the size 
of the cohort (n=156) was not large enough to see such an effect.   
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Almost half of participants took 5 or more solid oral medicines daily, which qualifies as 
polypharmacy by definition of some published studies (D. Gnjidic et al., 2012; U. Junius-
Walker et al., 2007; D. Koper et al., 2013). In addition, there was a significant relationship 
between dysphagia (SSQ) score and number of oral medicines taken on a daily basis. Marquis 
et al. did not find a significant relationship between difficulties in swallowing solid medicines 
and number of prescribed tablets among primary care adult patients who have at least 3 daily 
solid oral medications prescribed (J. Marquis et al., 2013). Marquis et al. (2013) used patients’ 
self-reported difficulties in swallowing solid medications instead of the validated 
questionnaire (SSQ) and this difference in methodology might have contributed to the 
deferring outcomes from the current study.  
 
It has been documented that size and shape of tablets and capsules affect the 
“swallowability” and oesophageal transit in adults. Generally, difficulty in swallowing tablets 
increases with size (H. Hey et al., 1982; A. B. Overgaard et al., 2001). However, most of the 
published studies are conducted in healthy young subjects and limited information is available 
on the ability of older adults especially those with swallowing difficulties to swallow tablets 
and capsules. In the current study, participants with dysphagia (SSQ scores > 200) were more 
likely to have difficulties in swallowing tablets and capsules of the given sizes and shapes 
compared to non-dysphagic participants. Oblong and oval tablets were considered slightly 
easier to swallow than flat round and arched round tablets, which is in agreement with 
previous reports that large tablets of oblong and oval shapes are easier to swallow and pass 
esophagus faster than round tablets (K. S. Channer and J. P. Virjee, 1985; H. Hey et al., 1982; 
A. B. Overgaard et al., 2001). Schiele et al. (2013) reported that round tablets of 8 mm in 
diameter started to cause swallowing difficulties in patients and for oval and oblong tablets 
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the length of tablets reached 15 mm and 16 mm respectively to causing problem in 
swallowing (J. T. Schiele et al., 2013).  
 
Amongst the alternative solid oral dosage forms, dispersible/effervescent tablets ranked 
highest in acceptability score. Previous use of dispersible/effervescent tablets has the highest 
proportion of participants giving a positive response. A national survey across the UK showed 
that 90% of what was prescribed or sold over the counter to older people for long-term use 
which were regarded as being “easy to swallow” were effervescent tablets (W. Baqir and A. 
Maguire, 2000). This familiarity with the type of the formulation and mode of administration 
might contribute to the high acceptance to these formulations.  
 
ODTs and mini-tablets were also deemed acceptable in both the dysphagia and non-
dysphagia populations, following dispersible tablets. The main advantages of ODTs reported 
by the participants were convenient to use and easier to swallow. Indeed, previous work has 
indicated that ODTs require less effort to swallow than conventional tablets in patients with 
dysphagia (G. Carnaby-Mann and M. Crary, 2005). The use of ODTs in older patients has been 
documented, especially in patients with Parkinson’s and Alzheimer’s diseases, and patients 
under antipsychotic treatments who might be purposely non-adherent (V. Danileviciute et al., 
2009; B. J. Kinon et al., 2003; P. A. Nausieda, 2005). The mini-tablets (4 mm in diameter) were 
considered easier to swallow than normal tablets due to small size by the participants. Mini-
tablets (3 mm) were deemed appropriate for use in patients with Parkinson’s disease, due to 
the potential of providing individualized dosage (S. Bredenberg et al., 2003). However, 
concerns were raised in respect of difficulties in handling and seeing these smaller 
formulations by participants in our study and the study contacted by S. Bredenberg et al. 
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(2003). Future research is needed in investigating acceptability of mini-tables of smaller sizes, 
multiple dosages and the potential of using dispensing devices in older patients.   
 
Chewable tablets and granules were considered as the least acceptable amongst the 
alternative dosage forms. Chewable tablets were useful in paediatric medicines for children 
over 2 years old (T. M. Michele et al., 2002). However, they might not be appropriate for use 
in older patients, as there has been a reported decline in chewing ability in older age primarily 
due to tooth loss (I. A. Kida et al., 2007; P. Peltola and M. M. Vehkalahti, 2005). Granules were 
not favored amongst the participants mostly due to reluctance in mixing medicines with food 
and concerns on incomplete dosing.  
 
For all of the alternative solid dosage forms, consistently higher acceptability scores were 
seen in the dysphagia population than in the non-dysphagia population. Participants with 
dysphagia (SSQ scores > 200) are more likely to experience problems in taking their medicines 
in the form of tablets and capsules. The current study shows that formulation characteristics 
play a role in medicine acceptability in older patients. It is therefore important to make 
available a variety of formulation choices for older patients who find swallowing tablets and 
capsule difficult. The European Union legislation in paediatric medicines has prompt the 
development of formulations suitable for children (P. Kozarewicz, 2014). The increasing 
availability of paediatric formulations could benefit older patients; however, there are distinct 
differences between the two populations (F. Liu et al., 2014). Consequently, explicit 
considerations should be given to the older population to address their unique and specific 
needs in drug therapy and medicine use.  
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The study has its limitations. The study recruited a convenient sample of community 
pharmacies which might introduce selection bias. The patients’ self-reported difficulties in 
swallowing solid medicines were not compared with the current medications prescribed to 
the patients which might have correlated better with the types and characteristics of 
formulations that the patients can or cannot take. Diagrams of tablets of different sizes and 
shapes (except for 9 mm tablets) were presented instead of real samples which might affect 
participants’ judgement in ability to swallow. The study focused on oral solid dosage forms 
and liquid medicines were not included. The need for liquid formulations might be higher in 
nursing homes and hospitals and these settings would be ideal to assess the acceptability to 
liquid medicines in future studies. The acceptance scores of the alternative dosage forms 
were not directly compared with that of tablets and capsules, which would be useful 
information for further investigation.  
 
5. Conclusions 
A significant proportion of older patients attending community pharmacies have symptoms 
compatible with dysphagia. These patients are more likely to have difficulties in swallowing 
tablets and capsules compared to those with no dysphagia. Healthcare professionals should 
identify patients with high risk of having problems swallowing their medicines and assist in 
selecting most appropriate medicine dosage forms. The development and availability of 
alternative oral formulations other than conventional tablets and capsules will likely to assist 
in medication administration and management in patient with dysphagia and might lead to 
better adherence. 
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Figure 1. Percentage of participants selecting the tablet size and shape that started to cause 
difficulty in swallowing. 
 
Fig 2. Percentage of participants selecting the capsule size that might start to cause difficulty 
in swallowing 
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Fig 3. Acceptability scores of different oral solid dosage forms (ODT: orally disintegrating 
tablet). 
Table 1. Products used to represent 9 mm tablets in different shapes 
Tablet shape Product used 
Flat round Imodium Instants tablets (McNeil Products Ltd ) 
Arched round 
Placebo tablets produced at University of 
Hertfordshire laboratories (Ingredients: 99% 
lactose monohydrate, 1% magnesium stearate, 
compressed using a CPR-6 single punch tablet 
press, Isopak Limited) 
Oblong Zirtek 10 mg tablets (UCB Pharma Limited) 
Oval 
Finasteride 5 mg tablets (Dr Reddy’s 
Laboratories (UK) Ltd) 
 
 
Table 2. Products used to represent various oral formulations 
Type of formulation Products used 
Capsule 
Hard gelatin capsule shells of sizes #00, #0, #1, 
#2, and #3 (supplied by Capsugel, Morristown, 
New Jersey, USA) filled with lactose monohydrate 
0.0
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Mini-tablet 
 
Round shaped mini-tablets (4 mm) was obtained 
as the content of Inconex XL 4 mg Prolonged-
release Capsules (Sandoz Ltd) 
Granules 
Fybogel sachet (Reckitt Benckiser Healthcare (UK) 
Ltd) 
Dispersible tablet 
Boots soluble paracetamol tablets (The Boots 
Company PCL) 
Orally disintegrating tablet 
(ODT) 
Imodium Instants melt (McNeil Products Ltd ) 
Chewable tablet 
Gaviscon double action chewable tablets (Reckitt 
Benckiser Healthcare (UK) Ltd) 
 
 
Table 3. Number of participants who had previously used the flexible solid oral formulations. 
Formulation 
Number (%) of participants who have 
previously used the formulation 
Mini-tablets 8 (5%) 
Granules 17 (11%) 
Dispersible/effervescent 
tablets 
107 (68%) 
Orally disintegrating 
tablets 
34 (22%) 
Chewable tablets 47 (30%) 
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Table 4. Participants’ impression on the flexible solid oral dosage forms.  2 
Formulation Advantages Participants 
(%) 
Disadvantages Participants 
(%) 
Dispersible/effervescent 
tablets 
 Easy to swallow; less harsh than 
swallowing tablets 
 Good for those with swallowing 
difficulties 
 Nice to drink 
19 
 
8 
 
40 
 Require water; takes long to 
dissolve 
 Cannot use on the move – takes 
long to dissolve  
 Concerns on taste 
 
5 
 
17 
 
38 
Mini-tablets  Small, easy to swallow 
 Good for those with swallowing 
difficulties 
 Can take more than one at once 
 Can be sprinkled onto food 
24 
23 
 
8 
6 
 Difficult to see for visually 
impaired 
 Do not want to mix food with 
medicine 
 If food is not completed 
consumed, patient does not 
receive full dose  
 Concerns on taste  
9 
 
23 
 
6 
 
 
28 
23 
 
23 
 
Granules  Good for those with swallowing 
difficulties  
 Can be sprinkled onto food 
 Come in various flavours 
 
26 
 
9 
11 
 Do not want to mix food with 
medicine: Presentation and 
flavour of food can be ruined 
 Opening sachet can be difficult for 
those with poor manual dexterity 
 Need to finish meal to get whole 
dose 
 Concerns on appearance 
 Concerns on taste 
28 
 
 
12 
 
9 
 
8 
15 
Orally disintegrating 
tablets 
 Melts itself, minimal effort and 
thought required 
 Good for those with swallowing 
difficulties 
 No water required: easy to take 
 Convenient/quick when on the 
go 
 
12 
 
10 
 
63 
10 
 Patients can be tempted to 
swallow early 
 Patients may remove formulation 
from the mouth before it is fully 
dispersed leading to sub-
therapeutic outcomes 
 Can leave residual and after-taste 
in the mouth 
 Concerns on taste 
7 
 
6 
 
 
 
5 
 
54 
24 
 
24 
 
Chewable tablets  No water required: Easy to use 
 Good for tablets which are too 
large and cannot be swallowed 
 Good for those with swallowing 
difficulties 
 It is sweet-like so does not 
appear as if you are taking a 
medicine   
18 
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9 
 
15 
 Patients who wear dentures 
cannot use.  
 Can get stuck in teeth – hard for 
those with dentures  
 Chewing time is long 
 Concerns on taste 
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